โ† All deals

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Public Equity (NASDAQ)BiotechGenomicsSequencing
๐Ÿ“ Menlo Park, CA
StreetZero Signal 51
Be the first to signal interest

About PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a leading provider of high-quality, long-read sequencing platforms based in Menlo Park, CA. The company empowers life scientists with highly accurate long-read sequencing through its innovative instruments using Single Molecule, Real-Time (SMRTยฎ) Sequencing technology. This technology delivers a comprehensive view of genomes, transcriptomes, and epigenomes.

LATEST FUNDINGRule 144
$33K
Announced 2026-11-17
๐Ÿ”’

Unlock the full deal profile

Create a free account to see investors, key highlights, news, company details and the AI analysis for PACIFIC BIOSCIENCES OF CALIFORNIA, INC..

Free plan includes 3 full deal profiles every month.

Investors

Key highlights

  • Completed $900 million convertible notes investment from SoftBank subsidiary in 2021.
  • Announced $150 million public offering of common stock in January 2023.
  • Maintains at-the-market equity facility for up to $100 million via Allen & Company.
  • NASDAQ-listed company with 64% institutional ownership.
  • Focuses on SMRT Sequencing technology for comprehensive genomic analysis.

Source document & SEC filing

The source SEC filing and the cached document are available to members only. Sign in to view and download them.

Sign in to view the filing Create free account